Biomedical potentialities of cationic geminis as modulating agents of liposome in drug delivery across biological barriers and cellular uptake

Int J Pharm. 2020 Sep 25:587:119640. doi: 10.1016/j.ijpharm.2020.119640. Epub 2020 Jul 13.

Abstract

Hydroxyethyl bearing gemini surfactants, alkanediyl-α,ω-bis(N-hexadecyl-N-2-hydroxyethyl-N-methylammonium bromide), 16-s-16(OH), were used to augment phosphatidylcholine based liposomes to achieve higher stability and enhanced cellular uptake and penetration. The developed liposomes were loaded with rhodamine B, doxorubicin hydrochloride, pralidoxime chloride to investigate release properties, cytotoxicity in vitro, as well as ability to cross the blood-brain barrier. At molar ratio of 35:1 (lipid:surfactant) the formulation was found to be of low toxicity, stable for two months, and able to deliver rhodamine B beyond the blood-brain barrier in rats. In vivo, pharmacokinetics of free and formulated 2-PAM in plasma and brain were evaluated, liposomal 2-PAM was found to reactivate 27% of brain acetylcholinesterase, which is, to our knowledge, the first example of such high degree of reactivation after intravenous administration of liposomal drug.

Keywords: Acetylcholine reactivation; Cationic liposome; Cellular uptake; Gemini surfactant; Targeted drug delivery.

MeSH terms

  • Animals
  • Cations
  • Doxorubicin
  • Drug Delivery Systems*
  • Liposomes*
  • Rats
  • Surface-Active Agents

Substances

  • Cations
  • Liposomes
  • Surface-Active Agents
  • Doxorubicin